VistaGen Therapeutics Inc (VTGN)
VistaGen Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for neuropsychiatric and neurological disorders. Its pipeline includes Fasedienol, an investigational pherine nasal spray in Phase III testing for anxiety in adults with social anxiety disorder, and Itruvone, a synthetic investigational neuroactive nasal spray in Phase II development for major depressive disorder. The company is also advancing PH80 for vasomotor symptoms and other women’s health disorders, PH15 for cognitive impairment linked to mental fatigue, PH284 for appetite loss associated with chronic conditions and cachexia, and AV-101, an oral prodrug targeting the N-methyl-D-aspartate receptor in the brain. VistaGen also has a licensing and collaboration agreement with AffaMed Therapeutics for fasedienol in multiple anxiety-related disorders. Founded in 1998, the company is headquartered in South San Francisco, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-VTGN
|
$0.39
|
70.6% Upside
|
Bargain
|
$1
|
336.7% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-0.1x
|
0.3x
|
7.4x
|
9.483 M
|
-34.963 M
|
9.9%
|
85.4%
|
-31.3
|
—
|
95.6%
|
